

ARBIOS SYSTEMS INC
Form 10-Q
November 18, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(MARK ONE)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2009

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from _____ to _____

Commission file number: 000-32603

ARBIOS SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or
organization)

91-1955323
(I.R.S. Employer Identification No.)

80 Commerce Drive, Allendale, NJ
(Address of principal executive offices)

07401
(Zip Code)

(201) 995-1919
(Registrant's telephone number, including area code)

530 S. Lake Avenue, Unit 363, Pasadena, CA 91101
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during

the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes
x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated filer <input type="radio"/>	Accelerated filer <input type="radio"/>
Non-accelerated filer <input type="radio"/>	Smaller reporting company <input checked="" type="radio"/>

(do not check if a smaller reporting company)

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

On September 30, 2009, there were 50,000,000 shares of common stock, \$.001 par value per share, issued and outstanding.

2

ARBIOS SYSTEMS, INC.
FORM 10-Q
TABLE OF CONTENTS

		PAGE NO.
PART I. FINANCIAL INFORMATION		
Item 1.	Financial Statements:	
	Condensed Balance Sheets as of September 30, 2009 (unaudited) and December 31, 2008 (audited)	4
	Condensed Statements of Operations for the three and nine months ended September 30, 2009 and 2008 and from August 23, 2000 (inception) through September 30, 2009 (unaudited)	5
	Condensed Statements of Cash Flows for the nine months ended September 30, 2009 and 2008 and from August 23, 2000 (inception) through September 30, 2009 (unaudited)	6
	Condensed Statement of Stockholders' Equity (Deficit) from August 23, 2000 (inception) through September 30, 2009 (unaudited)	7
	Notes to Condensed Financial Statements	12
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Qualitative and Quantitative Disclosures About Market Risk.....	23
Item 4T.	Controls and Procedures	23
PART II. OTHER INFORMATION		
Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Submission of Matters to a Vote of Security Holders	24

Item 5.	Other Information	24
Item 6.	Exhibits	24
SIGNATURES		25

PART I - FINANCIAL INFORMATION

ITEM 1. Condensed Financial Statements

ARBIOS SYSTEMS, INC.
(A Development Stage Company)
CONDENSED BALANCE SHEETS

	Successor September 30, 2009 (Unaudited)	Predecessor December 31, 2008
ASSETS		
Current assets		
Cash	\$ 193,815	\$ 370,686
Cash held in attorney trust	270,323	-
Prepaid expenses	-	21,506
Total current assets	464,138	392,192
Receivable	-	200,000
Property and equipment, net	-	6,177
Investment	-	86,209
Other assets	-	750
Total assets	\$ 464,138	\$ 685,328
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
Current liabilities		
Accounts payable	\$ 470,870	\$ 194,046
Accrued expenses	-	286,888
Total current liabilities	470,870	480,934
Long term contract obligations	-	150,000
Total liabilities	470,870	630,934
Stockholders' equity (deficit)		
Successor common stock, \$.001 par value; 100,000,000 shares authorized; 50,000,000 shares issued and outstanding at September 30, 2009	50,000	-
Predecessor common stock, \$.001 par value; 100,000,000 shares authorized; 25,792,747 shares issued and outstanding at December 31, 2008	-	25,792
Additional paid-in capital	143,256	21,617,075
Receivable for stock issuance	(199,988)	-
Deficit accumulated during the development stage	-	(21,588,473)
Total stockholders' equity (deficit)	(6,732)	54,394
Total liabilities and stockholders' equity (deficit)	\$ 464,138	\$ 685,328

The accompanying notes are an integral part of these condensed financial statements.

ARBIOS SYSTEMS, INC.
(A Development Stage Company)
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)

	Predecessor For the three months ended September 30, 2009	Predecessor For the three months ended September 30, 2008	Predecessor For the nine months ended September 30, 2009	Predecessor For the nine months ended September 30, 2008	Predecessor Inception to September 30, 2009
Revenues	\$ -	\$ -	\$ -	\$ -	\$ 320,966
Operating expenses:					
General and administrative	256,348	147,103	660,795	1,358,718	13,902,846
Research and development	-	164,350	-	1,220,747	9,325,632
Total operating expenses	256,348	311,453	660,795	2,579,465	23,228,478
Operating loss	(256,348)	(311,453)	(660,795)	(2,579,465)	(22,907,512)
Other income (expense):					
Loss from disposition of fixed assets	(3,120)	-	(3,120)	-	(3,120)
Interest income	-	3,786	229	32,264	497,748
Gain on sale of HepatAssist program, net	-	-	-	-	404,863
Loss on investment	-	-	(86,209)	-	(86,209)
Interest expense	-	-	-	-	(244,138)
Total other income (expense)	(3,120)	3,786	(89,100)	32,264	569,144
Loss before reorganization items, net	(259,468)	(307,667)	(749,895)	(2,547,201)	(22,338,368)
Reorganization items, net	147,885	-	(111,243)	-	(111,243)
Net loss	\$ (111,583)	\$ (307,667)	\$ (861,138)	\$ (2,547,201)	\$ (22,449,611)
Net loss per share:					
Basic and diluted	\$ (0.00)	\$ (0.01)	\$ (0.03)	\$ (0.10)	
Weighted-average shares:					
Basic and diluted	26,892,442	25,792,747	25,249,003	25,712,950	

The accompanying notes are an integral part of these condensed financial statements.

ARBIOS SYSTEMS, INC.
(A Development Stage Company)
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)

	Predecessor For the nine months ended September 30, 2009	Predecessor 2008	Predecessor Inception to September 30, 2009
Cash flows from operating activities:			
Net loss	\$ (861,138)	\$ (2,547,201)	\$ (22,449,611)
Adjustments to reconcile net loss to net cash used in operating activities:			
Amortization of debt discount	-	-	244,795
Depreciation and amortization	2,757	32,190	338,794
Patent rights impairment	-	-	91,694
Issuance of common stock, options and warrants for compensation	-	441,055	4,071,460
Issuance of warrants for patent acquisition	-	-	74,570
Settlement of accrued expense	-	-	54,401
Deferred compensation costs	-	-	319,553
Loss on disposition of fixed assets	3,120	2,207	8,157
Loss on disposition of investment	86,209	-	86,209
Gain on sale of HepatAssist program, net	-	-	(404,863)
Non-cash reorganization items, net	(226,103)	-	(226,103)
Changes in operating assets and liabilities:			
Prepaid expenses	21,506	35,459	-
Deferred financing costs	-	16,757	-
Other assets	750	68,686	-
Accounts payable	322,927	(114,149)	516,971
Accrued expenses	(106,888)	(97,367)	86,498
Other liabilities	-	-	64,695
Contract obligations	(150,000)	(100,000)	-
Net cash used in operating activities	(906,860)	(2,262,363)	(17,122,780)
Cash flows from investing activities:			
Additions of property and equipment	-	-	(149,467)
Proceeds from sale of fixed assets	300	4,175	4,476
Proceeds from sale of HepatAssist program	200,000	-	450,000
Purchase of short term investments	-	-	(21,866,787)
Maturities of short term investments	-	-	21,866,787
Net cash provided from investing activities	200,300	4,175	305,009
Cash flows from financing activities:			
Proceeds from issuance of convertible debt	-	-	400,000
Proceeds from common stock option/warrant exercise	-	-	67,900
Net proceeds from issuance of common stock and warrants	800,012	-	16,597,092
Net proceeds from issuance of preferred stock	-	-	238,732
Payments on capital lease obligation, net	-	-	(21,815)
Net cash provided by financing activities	800,012	-	17,281,909

Edgar Filing: ARBIOS SYSTEMS INC - Form 10-Q

Net (decrease) increase in cash	93,452	(2,258,188)	464,138
Cash at beginning of period	370,686	2,735,944	-
Cash at end of period	\$ 464,138	\$ 477,756	\$ 464,138
Supplemental disclosures of non-cash financing activity			
Issuance of securities for obligation related to finder's fees	\$ -	\$ -	\$ 47,500

The accompanying notes are an integral part of these condensed financial statements.

ARBIOS SYSTEMS, INC.
(A Development Stage Company)
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
PERIOD FROM AUGUST 23, 2000 (INCEPTION) TO SEPTEMBER 30, 2009
(Unaudited)

	Preferred Stock		Common Stock		Additional Receivable for Stock Issuance		Deferred Costs	Deficit Accumulated During the Development Stage	Total	
	Shares	Amount	Shares	Amount	Paid-In Capital					
Balance, August 23, 2000 (inception) restated for effect of reverse merger with Historical Autographs U.S.A. Inc.	-	\$ -	-	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	-
Stock issuance in exchange for cash			5,000,000	50	4,950					5,000
Net loss								(9,454)		(9,454)
Balance, December 31, 2000, as restated	-	-	5,000,000	50	4,950	-	-	(9,454)		(4,454)
Issuance of junior preferred stock for cash of \$250,000 and in exchange for \$400,000 in patent rights, research and development costs, and employee loanout costs less issuance expenses	681,818	7			958,278		(343,553)			614,732

of \$11,268, June
29, 2001

Issuance of
common stock in
exchange
for patent rights
and deferred
research
and development
costs

362,669 4 547,284 547,288

Services
receivable

(550,000) (550,000)

Deferred
employee
loan-out costs
receivable
earned

82,888 82,888

Net loss

(237,574) (237,574)

Balance,
December 31,
2001

681,818 7 5,362,669 54 1,510,512 - (810,665) (247,028) 452,880

The accompanying notes are an integral part of these condensed financial statements.

ARBIOS SYSTEMS, INC.
(A Development Stage Company)
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
PERIOD FROM AUGUST 23, 2000 (INCEPTION) TO SEPTEMBER 30, 2009
(Unaudited)

	Preferred Stock		Common Stock		Paid-In Capital	Additional Receivable for Stock Issuance	Deferred Costs	Deficit Accumulated During the Development Stage	Total
	Shares	Amount	Shares	Amount					
Amendment of December 31, 2001 agreement for the issuance of common stock agreement in exchange for research and development services					(495,599)		550,000		54,401
Deferred employee loan out costs receivable earned							171,776		171,776
Issuance of common stock for compensation			70,000	1	10,499				10,500
Issuance of common stock for cash			999,111	9	149,857				149,866
Net loss								(494,780)	(494,780)
Balance, December 31, 2002	681,818	7	6,431,780	64	1,175,269	-	(88,889)	(741,808)	344,643
Issuance of common stock for cash			417,000	417	246,827				247,244

less issuance expense of \$2,956				
Issuance of common stock in private placement for cash less issuance expense of \$519,230	4,000,000	4,000	3,476,770	3,480,770
Issuance of common stock for convertible debenture less issuance expense of \$49,500	400,000	400	350,100	350,500
Shares issued in connection with acquisition of Historical Autographs U.S.A., Inc. on October 30, 2003	1,220,000	8,263	(8,263)	-

The accompanying notes are an integral part of these condensed financial statements.

ARBIOS SYSTEMS, INC.
(A Development Stage Company)
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
PERIOD FROM AUGUST 23, 2000 (INCEPTION) TO SEPTEMBER 30, 2009
(Unaudited)

	Preferred Stock		Common Stock		Additional Paid-In Capital	Receivable for Stock Issuance Costs	Deferred Development Stage	Deficit Accumulated During the	Total
	Shares	Amount	Shares	Amount					
Value of warrants and beneficial conversion feature of bridge loan					244,795				244,795
Deferred employee loan-out costs receivable earned						88,889			88,889
Preferred Stock converted to Common Stock	(681,818)	(7)	681,818	7					-
Net loss							(885,693)		(885,693)
Balance, December 31, 2003	-	-	13,150,598	13,151	5,485,498	-	-	(1,627,501)	3,871,148
Issuance of common stock options and warrants for compensation					972,430				972,430
Exercise of common stock options			18,000	18	2,682				2,700
Issuance of securities for payable			47,499	47	47,451				47,498

Net loss							(3,327,827)	(3,327,827)
Balance, December 31, 2004	-	-	13,216,097	13,216	6,508,061	-	-	(4,955,328) 1,565,949
Issuance of common stock in private placement for cash less issuance expense of \$384,312			2,991,812	2,992	6,224,601			6,227,593
Issuance of common stock options and warrants for compensation					557,080			557,080
Exercise of common stock options			25,000	25	62,475			62,500

The accompanying notes are an integral part of these condensed financial statements.

ARBIOS SYSTEMS, INC.
(A Development Stage Company)
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
PERIOD FROM AUGUST 23, 2000 (INCEPTION) TO SEPTEMBER 30, 2009
(Unaudited)

	Preferred Stock Shares	Preferred Stock Amount	Common Stock Shares	Common Stock Amount	Additional Paid-In Capital	Receivable for Stock Issuance	Deferred Development Costs	Deficit Accumulated During the Stage	Total
Net loss								(3,823,903)	(3,823,903)
Balance, December 31, 2005	-	-	16,232,909	16,233	13,352,217	-	-	(8,779,231)	4,589,219
Issuance of common stock in private placement for cash less issuance expense of \$95,013			1,227,272	1,227	1,253,760				1,254,987
Issuance of common stock options and warrants for compensation					703,839				703,839
Stock warrant term extension			-		482,964				482,964
Warrant liability					(1,284,841)				(1,284,841)
Net loss								(4,461,904)	(4,461,904)
Balance, December 31, 2006	-	-	17,460,181	17,460	14,507,939	-	-	(13,241,135)	1,284,264
Cumulative effect of change in accounting principle:									

Adjust retained earnings at January 1, 2007 for change in accounting principle				(521,187)	(521,187)
Reclassification of warrants		1,284,841			1,284,841
Issuance of common stock and warrants in private placement for cash less issuance expense of \$377,169	7,478,462	7,479	4,476,352		4,483,831
Exercise of common stock warrants	18,000	18	2,682		2,700
Stock option based compensation expense			438,263		438,263

The accompanying notes are an integral part of these condensed financial statements.

ARBIOS SYSTEMS, INC.
(A Development Stage Company)
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)
PERIOD FROM AUGUST 23, 2000 (INCEPTION) TO SEPTEMBER 30, 2009
(Unaudited)

	Preferred Stock Shares	Common Stock Shares	Common Stock Amount	Additional Paid-In Capital	Receivable for Stock Issuance	Deferred Development Costs	Deficit Accumulated During the Stage	Total
Stock warrant term extension		-		59,025				59,025
Restricted stock based compensation expense		621,818	621	315,604				316,225
Issuance of warrants for patent acquisition				74,570				74,570
Net loss							(5,552,650)	(5,552,650)
Balance, December 31, 2007	-	25,578,461	25,578	21,159,276	-	-	(19,314,972)	1,869,882
Stock option based compensation expense				114,824				114,824
Stock warrant term extension				175,256				175,256
Restricted stock based compensation expense				107,933				107,933
Issuance of common stock for compensation		214,286	214	59,786				60,000
Net loss							(2,273,501)	(2,273,501)
Balance, December 31, 2008	-	25,792,747	25,792	21,617,075	-	-	(21,588,473)	54,394
		(1,436,500)	(1,436)	1,436				-

Common stock shares surrendered by shareholder									
Arbios Acquisition Partners capital contribution			1,000,000	(199,988)				800,012	
Chapter 11 Plan of reorganization: Cancellation of existing equity	(24,356,247)	(24,356)	24,356						-
Issuance of new common stock	50,000,000	50,000	(50,000)						-
Post reorganization fresh start accounting			(22,449,611)			22,449,611			-
Net loss						(861,138)		(861,138)	
Balance, September 30, 2009	-	-	50,000,000	\$ 50,000	\$ 143,256	\$ (199,988)	\$ -	\$ -	(6,732)

The accompanying notes are an integral part of these condensed financial statements.

Arbios Systems, Inc.
(A Development Stage Company)
Notes to Condensed Financial Statements (Unaudited)
Nine Months Ended September 30, 2009

(1) Basis of Presentation

Arbios Systems, Inc. is a Delaware corporation with its corporate office in Allendale, New Jersey. To date, our goal was to seek to develop, manufacture and market liver assist therapies to meet the urgent need for medical treatment of liver failure.

Since Arbios Systems, Inc. was incorporated in February 1999, we have been a medical device and cell-therapy company that was focused on the development of products for the treatment of liver failure. Our lead product candidate was under development during 2008 and consisted of a novel extracorporeal blood purification therapy called the SEPET™ Liver Assist Device. Until recently, we also owned the rights to an extracorporeal, bioartificial liver therapy referred to as the HepatAssist™ Cell-Based Liver Support System which incorporated porcine pig liver cells, which we sold to HepaLife Technologies, Inc. in October 2008. Because of our limited financial resources, all of our development activities during the past few years have focused on our SEPET™ Liver Assist Device. In February 2008, the U.S. Food and Drug Administration (“FDA”) granted us conditional approval of an Investigational Device Exemption, or IDE, application to begin the pivotal clinical trial for SEPET™. In May 2008, we received approval to begin the first segment of our pivotal clinical trial for SEPET™. The budget to complete this clinical trial and our other projected operating expenses, however, far exceeded the limited financial resources available to us at that time, and we have, therefore, not commenced the clinical trial.

As a development stage company engaged solely in the development of new products, we did not generate revenues from our activities and, accordingly, we were solely dependent upon our ability to raise funding from investors to finance both our operating expenses and the cost of developing our technologies. Due in part to the global economic crisis that commenced in 2008 and the dramatic decline in the availability of financing, particularly to development stage companies, we were unable to raise the capital we needed to finance our operational and developmental activities. As a result, in order to preserve our remaining cash while seeking financing and while attempting to otherwise maximize the value of our assets, in mid-2008, we terminated all of our employees and suspended the majority of our operations. Since then, our activities had been conducted by our interim Chief Executive Officer and our interim Chief Financial Officer, both of whom were engaged as part-time consultants. We have not conducted any active operations since mid-2008, and our sole activity since that time has been to (i) seek sufficient capital to re-initiate our operations, (ii) find a strategic partner to co-develop our technologies with us, or (iii) sell our technologies and assets in a manner that will maximize shareholder value. Consistent with this plan, in October 2008, we sold the HepatAssist™ Cell-Based Liver Support System to HepaLife Technologies, Inc. (“HepaLife”) for (a) \$450,000 in cash, of which \$250,000 was paid in October 2008 and the remaining \$200,000 was deferred for up to 18 months from the date of sale, and (b) a warrant to purchase 750,000 shares of HepaLife common stock at an exercise price of \$0.35 per share. On April 22, 2009, HepaLife paid us the \$200,000 deferred payment immediately, in return for the cancellation of the warrant to purchase 750,000 shares of HepaLife common stock that was part of the consideration in our sale of HepatAssist™ to HepaLife.

Liquidity and Going Concern

The accompanying condensed financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred a net operating loss of \$861,138 for the nine months ended September 30, 2009 and an accumulated deficit of \$22,449,611 before fresh start. In addition, at September 30, 2009, the Company’s working capital is (\$6,732). These

factors raise substantial doubt about the Company's ability to continue as a going concern.

12

Voluntary Chapter 11 Filing

On January 9, 2009, the Company filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) with the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), Case Number 09-10082 (the “Bankruptcy”). We had operated as a debtor-in-possession under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court until September 21, 2009, the date our Plan of Reorganization became effective and a new Board of Directors and management were appointed.

Plan of Reorganization; Recapitalization of our Company

On April 3, 2009, the Company filed a motion to conditionally approve our Chapter 11 Plan of Reorganization as the disclosure statement (the motion to conditionally approve the disclosure statement and the Plan of Reorganization is herein referred to as the “Plan”). On April 20, 2009, the Bankruptcy Court confirmed the use of the Plan of Reorganization as a disclosure statement. Arbios Acquisition Partners had agreed to pay a total of \$1 million to fund Arbios in consideration for 1) 90% of the new shares to be issued and 2) payments to class 1 creditors who would receive 90% of the amounts owed to them upon effectiveness of the Plan.

On September 21, 2009 (the “effective date”) Arbios Systems Inc.’s previously disclosed confirmed Chapter 11 Plan of Reorganization in Arbios’ Chapter 11 Bankruptcy filing in the United States Bankruptcy Court for the District of Delaware, Case No. 09-10082, became effective. Pursuant to the terms of the Chapter 11 Plan, among other things, as of the effective date:

- All of Arbios’ currently existing equity (including, but not limited to, all of its outstanding common and preferred shares of stock, warrants, and options) were canceled as of the effective date. Since there were no material changes to the financial statements between the effective date and end of the third quarter, the Company has elected to use September 30, 2009 as the fresh start date referenced in footnote 2 below.
- The company issued to Arbios Acquisition Partners, LLC an unrelated, privately held company, and its designees, who were the funders under the Chapter 11 Plan, an aggregate of 45 million new shares of common stock representing 90% of Arbios’ newly issued shares.
- The company issued to the Company’s existing shareholders an aggregate of 5 million new shares of common stock equal to 10% of its newly issued shares pro rata, which replaces the canceled shares of common stock. As a result, pursuant to the Chapter 11 Plan, 1 newly issued share of Arbios common stock replaced every 4.87 canceled shares of Arbios common stock held by Arbios shareholders as of September 21, 2009.
- The officers and directors, as of the effective date of the Chapter 11 Plan, resigned and new officers and directors were elected.

In consideration for issuing the new shares to shareholders, Arbios Acquisition Partners and its designees paid the company \$800,000 in cash. Of the 45 million new shares of common stock issuable to Arbios Acquisition Partners and its designees, Arbios Acquisition Partners were issued 30 million shares as of the effective date of the Chapter 11 Plan, representing 60% of the issued and outstanding new shares of common stock for \$533,333, and Arbios Acquisition Partners’ ten designees, none of which are affiliated with Arbios Acquisition Partners, were issued 15

million shares for \$266,667 as of the effective date of the Chapter 11 Plan, which has been paid.

Arbios Acquisition Partners has advised the Company that the remaining \$200,000 called for under the Chapter 11 Plan will be provided in the future on an as-needed basis on terms and conditions to be determined.

Arbios Acquisition Partners, LLC was founded by Thomas J. Fagan to fund Arbios in consideration for 90% of Arbios' new common stock in connection with Arbios' reorganization as provided in Arbios' Chapter 11 Plan. Mr. Fagan is the sole Manager of Arbios Acquisition Partners. Energex Systems, Inc., a developer, manufacturer and marketer of patented medical technologies, currently owns approximately 85% of the membership interests of Arbios Acquisition Partners. Thomas Fagan is the Chairman of the Board, President, Chief Executive Officer, a director and the principal stockholder of Energex Systems, Inc.

Arbios believes that the funds used by Arbios Acquisition Partners and its designees to purchase their respective new shares of common stock were raised by Arbios Acquisition Partners through the private sale of Arbios Acquisition Partners membership interests, and were personal funds of the designees, respectively.

The unaudited condensed financial statements and notes are presented as permitted by Form 10-Q. These unaudited condensed financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures, normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America, have been omitted pursuant to such SEC rules and regulations. In the opinion of the management of the Company, the accompanying unaudited condensed financial statements include all adjustments, including those that are normal and recurring considered necessary to present fairly the financial position of the Company as of September 30, 2009, and the results of operations for the periods presented. These unaudited condensed financial statements should be read in conjunction with the Company's audited financial statements and the accompanying notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 as filed with the SEC. Because of the Bankruptcy and the change in the Company's ownership and management, the Company expects that its operating results will vary from its operating results before the Bankruptcy. Therefore, period-to-period comparisons should not be relied upon as predictive of the results in future periods. The results of operations for the nine months ended September 30, 2009 are not necessarily indicative of the results to be expected for any subsequent periods or for the entire 2009 fiscal year.

Sale of HepaLife Technologies, Inc. Warrant

Pursuant to a Bankruptcy Court Order, on April 22, 2009, the Company sold the five-year Series D warrant to purchase up to 750,000 shares of HepaLife's common stock at an exercise price of \$0.35 per share (the "Warrant") back to HepaLife in consideration for the early payment of the \$200,000 Deferred Purchase Price, which funds were received by the Company on April 22, 2009. The closing price of HepaLife's common stock on the OTC Bulletin Board on April 22, 2009 was \$0.19 per share. The surrender of the Warrant in exchange for the acceleration of the \$200,000 Deferred Purchase Price payment resulted in a "loss on investment" of \$86,209.

Termination of Immunocept, LLC License Agreement

On January 2, 2009, Immunocept, LLC declared a default in the foregoing license with the Company. On May 26, 2009, Immunocept filed an amended proof of claim in the amount of \$3.2 million plus unliquidated damages. In turn, the Company moved to reject the License Agreement with the Bankruptcy Court on May 28, 2009. As part of the rejection of the License Agreement, the Company objected to Immunocept's damages claims and filed a modified Plan of Reorganization that rejected assumption of this License Agreement on June 9, 2009. The confirmation of the Plan occurred on June 22, 2009. In an effort to end the costly litigation in this matter and to move the Plan of Reorganization forward with the Court, the Company and Immunocept LLC reached a settlement on July 21, 2009.

Pursuant to the settlement agreement between Arbios Systems, Inc. and Immunocept, LLC, the license agreement was terminated on June 22, 2009 and the Company agreed that Immunocept, LLC would receive a pre-petition claim of \$350,000 (paid at 90%). The Company has acknowledged that it owed \$100,000 to Immunocept, LLC on January 1, 2009, as part of a milestone payment, along with an additional \$150,000 payment due for the issuance of a new patent. Arbios will also pay up to \$100,000 to Immunocept as part of the settlement agreement for legal and administrative costs. Immunocept will have no rights to the pre-clinical, clinical data, or IDE for SEPET devices and the Company shall remain bound by confidentiality regarding the Immunocept, LLC patent portfolio.

2. Fresh Start Consolidated Statement of Financial Position

On the Effective Date, we adopted fresh-start accounting in accordance with ASC 852 Reorganization, formerly American Institute of Certified Public Accountants' Statement of Position 90-7, Financial Reporting by Entities in Reorganization Under the Bankruptcy Code ("SOP 90-7") as amended by Financial Accounting Standards Board ("FASB") Staff Position No. SOP 90-7-1, An Amendment of AICPA Statement of Position 90-7. This resulted in our becoming a new reporting entity on September 30, 2009, which has a new capital structure, a new basis in the identifiable assets and liabilities assumed and no retained earnings or accumulated losses. Accordingly, the Consolidated Financial Statements on or after September 30, 2009 are not comparable to the Consolidated Financial Statements prior to that date.

Fresh-start accounting reflects our value as determined in the confirmed Plan. Under fresh-start accounting, our asset values are re-measured using fair value and are allocated in accordance with ASC 805 Business Combinations, formerly Statement of Financial Accounting Standards ("SFAS") No. 141, Business Combinations ("SFAS No. 141"). In addition, fresh-start accounting also requires that all liabilities, other than deferred taxes, should be stated at fair value or at the present values of the amounts to be paid using appropriate market interest rates. Deferred taxes are determined in conformity with ASC 740, Income Taxes, formerly SFAS No. 109, Accounting for Income Taxes ("SFAS No. 109").

All estimates, assumptions, valuations, appraisals and financial projections, including the fair value adjustments, the financial projections, the enterprise value and equity value, are inherently subject to significant uncertainties and the resolution of contingencies beyond our control. Accordingly, there can be no assurance that the estimates, assumptions, valuations, appraisals and the financial projections will be realized and actual results could vary materially. In accordance with generally accepted accounting principles, the preliminary allocation of the enterprise value is subject to additional adjustment within one year after emergence from bankruptcy when additional or improved information on valuations becomes available. We do not expect that adjustments to recorded fair values will be made since our assets are comprised of cash balances and our liabilities are comprised of accounts payable that have been satisfied subsequent to September 30, 2009.

The adjustments set forth in the following Fresh Start Consolidated Statement of Financial Position in the columns captioned "Effect of Plan" and "Revaluation of Assets and Liabilities" reflect the effect of the consummation of the transactions contemplated by the Plan, including the settlement of various liabilities, securities issuances, incurrence of new indebtedness and cash payments, and the revaluation of our assets and liabilities to reflect their fair value under fresh-start accounting. The adjustments resulted in a pre-tax net effect of discharge of claims and liabilities of \$46,103 under the Plan.

ARBIOS SYSTEMS, INC
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)

The effects of the Plan and fresh-start accounting on our Consolidated Balance Sheet at September 30, 2009 are as follows:

	Predecessor		Revaluation of Assets and Liabilities	Successor
	September 29, 2009	Effect of Plan		September 30, 2009
ASSETS				
Current Assets:				
Cash	\$ -	193,815 (b)		\$ 193,815
Restricted cash	199,112	(199,112) (b)		
Cash held in attorney trust	-	270,323 (b)		270,323
Total Assets	\$ 199,112			\$ 464,138
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)				
Current Liabilities:				
Accounts payable	\$ 391,818	79,052 (a,b)		\$ 470,870
Deposit from Arbios Acquisition Partners LLC	199,112	(199,112) (b)		-
Accrued expenses	180,000	(180,000) (c)		-
Total Current Liabilities	770,930			470,870
Liabilities subject to compromise under				
reorganization proceeding	461,029	(461,029) (a)		-
Shareholders' Equity (Deficit):				
Successor common stock at \$0.001 par value	-	50,000 (b)		50,000
Predecessor common stock at \$0.001 par value	24,356	(24,356) (c)		-
Additional contributed capital	21,618,511	974,356 (b)	(22,449,611) (c)	143,256
Receivable for stock issuance	-	(199,988) (b)		(199,988)
Accumulated deficit	(22,675,714)	226,103 (a,b)	22,449,611 (c)	-
Total Shareholders' Equity (Deficit)	(1,032,847)			(6,732)
Total Liabilities and Shareholders' Equity (Deficit)	\$ 199,112			\$ 464,138

(a) To record the discharge and payment of liabilities subject to compromise.

- (b) The company issued to Arbios Acquisition Partners, LLC an unrelated, privately held company, and its designees, who were the funders under the Chapter 11 Plan, an aggregate of 45 million new shares of common stock representing 90% of Arbios' newly issued shares for \$800,012 in cash. An additional \$199,988 is due per the Plan of Reorganization; the timing and nature of this infusion to be determined on as needed basis. The company issued to the Company's existing shareholders an aggregate of 5 million new shares of common stock equal to 10% of its newly issued shares pro rata, which replaces the canceled shares of common stock. As a result, pursuant to the Chapter 11 Plan, 1 newly issued share of Arbios common stock replaced every 4.87 canceled shares of Arbios common stock held by Arbios shareholders as of September 21, 2009.
- (c) To record cancellation of Predecessor common stock, close out of remaining equity balances of Predecessor in accordance with fresh-start accounting. The cancellation of all common stock, options and warrants in conjunction with the Chapter 11 Plan of Reorganization confirmed on September 21, 2009 resulted in the reversal of an accrued liquidated damages liability of \$180,000.

Liabilities Subject to Compromise

Liabilities subject to compromise refers to pre-petition obligations that were impacted by the Chapter 11 Case. The amounts represented our estimate of known or potential obligations to be resolved in connection with our Chapter 11 Case. The following table summarizes the components of liabilities subject to compromise included in our balance sheet as of September 29, 2009:

	Predecessor September 29, 2009
Pre-petition accounts payable	\$ 111,029
Debt owed to Immunocept, LLC	350,000
Total Liabilities Subject to Compromise	\$ 461,029

Reorganization Items, net

Reorganization items, net are presented separately in the Consolidated Statement of Operations and represent items of income, expense, gain or loss that we realized or incurred due to our reorganization under Chapter 11 of the U.S. Bankruptcy Code.

Reorganization items consisted of the following items:

	Predecessor	
	Three Months Ended September 30, 2009	Nine Months Ended September 30, 2009
Discharge of claims and liabilities (a)	\$ (46,103)	\$ (46,103)
Professional fees (b)	78,218	337,346
Change in liquidated damages liability(c)	(180,000)	(180,000)
Total Reorganization Items, net	\$ (147,885)	\$ 111,243
Cash effect of reorganization items:		
Professional fees	\$ 78,218	\$ 337,346

- (a) The discharge of claims and liabilities primarily relates to allowed general, unsecured claims in our Chapter 11 proceedings which represent a 10% reduction in our outstanding accounts payable and liabilities at the time of our Chapter 11 filing.
- (b) Professional fees for services provided by debtor and creditor professionals directly related to our reorganization proceedings.
- (c) The cancellation of all common stock, options and warrants in conjunction with the Chapter 11 Plan of Reorganization confirmed on September 21, 2009 resulted in the reversal of an accrued liquidated damages liability of \$180,000.

(3) Recent Accounting Pronouncements

In June 2009, the Financial Accounting Standards Board (“FASB”) issued ASC 105, Generally Accepted Accounting Principles which establishes the FASB Accounting Standards Codification (the “Codification” or “ASC”) as the source of authoritative accounting principles to be applied by nongovernmental entities in the preparation of financial statements in conformity with U.S. GAAP. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative U.S. GAAP for SEC registrants. All guidance contained in the Codification carries an equal level of authority. ASC 105 is effective for financial statements issued for interim and annual periods ending after September 15, 2009. The Codification will supersede all existing non-SEC accounting and reporting standards. All other non-grandfathered, non-SEC accounting literature not included in the Codification will become non-authoritative. Following ASC 105, the FASB will not issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts. Instead, it will issue Accounting Standards Updates. The FASB will not consider Accounting Standards Updates as authoritative in their own right. Accounting Standards Updates will serve only to update the Codification, provide background information about the guidance and provide the bases for conclusions on the change(s) in the Codification. The Company adopted ASC 105 in its Form 10-Q for the quarter ended September 30, 2009. The adoption did not have an impact on the Company’s unaudited condensed consolidated results of operations and financial condition for the three and nine months ended September 30, 2009.

In April 2009, the FASB issued additional requirements regarding interim disclosures about the fair value of financial instruments which were previously only disclosed on an annual basis. Entities are now required to disclose the fair value of financial instruments which are not recorded at fair value in the financial statements in both their interim and annual financial statements. The new requirements were effective for interim and annual periods ending after June 15, 2009 on a prospective basis. There was no impact on the Company’s financial results as this relates only to additional disclosures.

In May 2009, the FASB issued ASC 855, Subsequent Events. ASC 855 establishes accounting principles and requirements for subsequent events. Specifically, ASC 855 sets forth the following: (a) the period after the balance sheet date during which management of an entity shall evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements, (b) the circumstances under which an entity shall recognize events or transactions occurring after the balance sheet date in its financial statements and (c) the disclosures that an entity shall make about events or transactions that occurred after the balance sheet date. ASC 855 requires entities to recognize in the financial statement, the effects of all subsequent events that provide additional evidence about conditions that existed at the date of the balance sheet, including estimates inherent in the process of preparing financial statements. Conversely, entities shall not recognize subsequent events that provide evidence about conditions that did not exist at the date of the balance sheet but arose after the balance sheet date but before financial statements are issued or are available to be issued. Entities shall disclose the date through which subsequent events have been evaluated, as well as whether that date is the date the financial statements were issued or the date the financial statements were available to be issued. Entities shall also disclose the nature and financial effect of nonrecognized subsequent events if such disclosure keeps the financial statements from being misleading. The Company adopted ASC 855, effective June 30, 2009.

As of June 30, 2009 the Company implemented FASB ASC 825-10-65-1, “Financial Instruments”. ASC 825-10-65-1 provides disclosure about fair value of financial instruments in interim as well as in annual financial statements. This guidance is effective for periods after June 15, 2009. In August 2009, the FASB issued ASU No. 2009-05, “Fair Value Measurements and Disclosures” (ASU 2009-05). ASU 2009-05 provided amendments to ASC 820-10, Fair Value Measurements and Disclosures – Overall,” for the fair value of liabilities. ASU 2009-05 provides clarification that in circumstances in which a quoted price in an active market for the identical liability is not available, a reporting entity is required to measure fair value using certain techniques. ASU 2009-05 also clarifies that when estimating the fair value of a liability, a reporting entity is not required to include a separate input or adjustment to other inputs relating to the existence of a restriction that prevents the transfer of a liability. ASU 2009-05 also clarifies that both a quoted

price in an active market for the identical liability at the measurement date and the quoted price for the identical liability when traded as an asset in an active market when no adjustments to the quoted price of the asset are Level fair value measurements. The new guidance is effective for interim and annual periods beginning after August 27, 2009, and applies to all fair-value liabilities required by GAAP. The Company is currently assessing the impact of the adoption of ASU 2009-05.

(4) Stock-Based Compensation:

During the three months ended September 30, 2009 and 2008, the Company recognized equity based compensation expense for stock options of \$0 and \$22,000, respectively, which was recognized in the Statement of Operations. During the nine months ended September 30, 2009 and 2008, the Company recognized equity based compensation expense for stock options of \$0 and \$98,000, respectively, which was recognized in the Statement of Operations in general and administrative expenses. As of September 30, 2009, there was no unrecognized compensation costs related to non-vested awards. The Plan of Reorganization confirmed on September 21, 2009 cancels all outstanding options on the date of confirmation.

(5) Subsequent Event

None.

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

SAFE HARBOR STATEMENT

In addition to historical information, the information included in this Quarterly Report on Form 10-Q contains forward-looking statements, such as those pertaining to the Chapter 11 bankruptcy proceeding. Forward-looking statements involve numerous risks and uncertainties and should not be relied upon as predictions of future events. Certain such forward-looking statements can be identified by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "pro forma," "estimates," or "anticipates" or other variations thereof or comparable terminology, or by discussions of strategy, plans or intentions. Such forward-looking statements are necessarily dependent on assumptions, data or methods that may be incorrect or imprecise and may be incapable of being realized. The following factors, among others, including those risks set forth under "Factors That May Affect our Business And Our Future Results and Market Price of Our Stock," included in Item 6 "Management's Discussion and Analysis of Plan of Operation" of our Annual Report on Form 10-K for the year ended December 31, 2008 and other filings we make with the Securities and Exchange Commission could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: need for a significant amount of additional capital, lack of revenue, uncertainty of product development, ability to obtain regulatory approvals in the United States and other countries, and competition. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect our management's analysis only. We assume no obligation to update forward-looking statements.

Overview

During the past few years, our efforts have been principally devoted to research and development activities, raising capital, and recruiting additional scientific and management personnel and advisors. We have not marketed or sold any product and have not generated any revenues from commercial activities.

In May 2008, we received approval from the FDA to commence a Phase II/III pivotal clinical trial for SEPETTM. We estimated that the cost of completing these trials was between \$5 million and \$10 million. As we have done since our inception, we intended to raise the funds to complete our development from financing transactions. Unfortunately, because of the global economic crisis that began in 2008 and the dramatic decline in the availability of financing, particularly to development stage companies like ours, we were unable to raise the capital we needed to finance our operations and development activities. As a result, in order to preserve our remaining cash while seeking financing and while attempting to otherwise maximize the value of our assets, in July of 2008 we terminated all of our employees and suspended most of our operations. We have not conducted any active operations since mid-2008, and our sole activity since that time has been to (i) seek sufficient capital to re-initiate our operations,

(ii) find a strategic partner to co-develop our technologies with us, or (iii) sell our technologies and assets in a manner that will maximize shareholder value.

19

On January 9, 2009, this Company filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code (the “Bankruptcy”) with the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). We are continuing to exist as a debtor-in-possession under the jurisdiction of the Bankruptcy Court.

On March 9, 2009, we entered into a Term Sheet with Arbios Acquisition Partners (“Acquisition Partners”) pursuant to which Acquisition Partners agreed to invest \$1,000,000 for the purchase of 90% of our common stock. The Bankruptcy Court confirmed the Plan on June 22, 2009. Through September 15, 2009, Acquisition Partners had paid us \$400,000 in installments (a portion of which was held in an escrow account). Another \$400,000 payment was then received, thereby permitting the transaction to be consummated (Acquisition Partners will provide the final \$200,000 following the Effective Date, on an as needed basis on terms and conditions to be determined). The Plan of Reorganization to approve that transaction has been submitted to our creditors and stockholders and approved according to the Plan of Reorganization. On September 21, 2009, the Plan of Reorganization became Effective and the Company may emerge from Chapter 11 when the new stock is issued to the shareholders per the provisions of the Plan of Reorganization.

In order to have sufficient funds to operate, in October 2008, we sold our HepatAssist™ Cell-Based Liver Support System to HepaLife Technologies, Inc. (“HepaLife”). We purchased HepatAssist™ in April 2004 for \$450,000 but had not further developed that technology. We sold our HepatAssist™ system to HepaLife for (a) \$450,000 in cash, of which \$250,000 was paid in October 2008 and \$200,000 was deferred for up to 18 months from the date of sale, and (b) a warrant to purchase 750,000 shares of Series D common stock at an exercise price of \$0.35 per share. HepaLife prepaid the \$200,000 deferred payment on April 22, 2009, in consideration for the cancellation of the warrant to purchase 750,000 shares of HepaLife Series D common stock.

As part of the Plan of Reorganization, all of our former officers and directors have resigned upon the Plan becoming effective and new officers and directors have been appointed upon the Plan of Reorganization becoming effective on September 21, 2009.

Critical Accounting Policies

This discussion is based on our unaudited condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these unaudited condensed financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, impairment of long-lived assets and their useful lives, including finite lived intangible costs, accrued liabilities and certain expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.

Our significant accounting policies are summarized in Note 1 to our audited financial statements for the year ended December 31, 2008 included in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our unaudited condensed financial statements:

Development Stage Enterprise

We are a development stage enterprise as defined by the ASC 915 Development Stage Entities, formerly, Financial Accounting Standards Board's, or FASB, Statement of Financial Accounting Standards, or SFAS, No. 7, "Accounting and Reporting by Development Stage Enterprises." All losses accumulated since our inception have been considered part of our development stage activities.

Cash

Cash consists of a checking account and cash held in an attorney trust account.

Stock-Based Compensation

Commencing January 1, 2006, we adopted ASC 718, formerly SFAS No. 123R, "Share Based Payment", or SFAS 123R, which requires all share based payments, including grants of stock options, to be recognized in the income statement as an operating expense, based on fair values.

Accounting for Uncertainty in Income Taxes

In July 2006, the FASB issued ASC 740, formerly Interpretation No. 48, "Accounting for Uncertainty in Income Taxes". This Interpretation clarifies the accounting for uncertainty in income taxes recognized in an entity's financial statements and prescribes a recognition threshold of more-likely-than-not to be sustained upon examination. Measurement of the tax uncertainty occurs if the recognition threshold has been met. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. In the normal course of business we are subject to examination by taxing authorities. At present, there are no ongoing audits or unresolved disputes with the various tax authorities that we file with. The adoption of ASC 740 on January 1, 2007 did not have any effect on our financial position, results of operations or cash flows as of or for the period ended September 30, 2009.

Results of Operations

Since we have been involved in developing our product candidates and do not have any products available for sale, we have not yet generated any revenue from sales. Inception to date revenue represents revenue recognized from an SBIR government grant.

General and administrative expenses of approximately \$256,000 and \$147,000 were incurred for the three months ended September 30, 2009 and 2008, respectively. General and administrative expenses for the three months ended September 30, 2009 increased by approximately \$109,000 from the prior year's level. The increase is primarily attributed to a \$178,000 increase in insurance costs resulting from director and officer insurance coverage for the former officers and directors. This increase is offset in part by an overall decline in virtually all expense categories as a result of curtailed operations due to a lack of capital resources and our voluntary Chapter 11 bankruptcy filing on January 9, 2009. General and administrative expenses of approximately \$661,000 and \$1,359,000 were incurred for the nine months ended September 30, 2009 and 2008, respectively. General and administrative expenses for the nine months ended September 30, 2009 decreased by approximately \$698,000 over the prior year level. The decrease is primarily attributed to a \$316,000 decrease in non cash option and warrant charges due to a decline in the number of stock options granted and a non recurring 2008 charge incurred for warrant extensions, a \$95,000 decline in payroll costs due to staff reductions and a \$167,000 decrease in legal and consulting fees from the curtailment of patent work and a decline in contract negotiating costs in 2009. In addition, there also was an overall decline in virtually all

expense categories as a result of curtailed operations due to a lack of capital resources and our voluntary Chapter 11 bankruptcy filing on January 9, 2009. The decrease is offset in part by an increase in insurance costs resulting from director and officer insurance coverage for the former officers and directors.

Research and development expenses of approximately \$0 and \$164,000 were incurred for the three months ended September 30, 2009 and 2008, respectively. The research and development expenses for the three months ended September 30, 2009 decreased by approximately \$164,000 over the comparable prior year level. Research and development expenses of approximately \$0 and \$1,221,000 were incurred for the nine months ended September 30, 2009 and 2008, respectively. The research and development expenses for the nine months ended September 30, 2009 decreased by approximately \$1,221,000 over the comparable prior year level. The decline in research and development expenses for the three and nine months ended September 30, 2009 is due to the curtailment of all research and development activities in the fourth quarter of 2008 due to a lack of capital resources and our voluntary Chapter 11 bankruptcy filing on January 9, 2009.

Reorganization items consist of legal expenses, reversal of an accrued liquidated damages liability and debt discharge. Legal expenses for the three and nine months ended September 30, 2009 were approximately \$78,000 and \$337,000, respectively, and consist primarily of legal fees incurred in the Bankruptcy proceedings.

The cancellation of all common stock, options and warrants in conjunction with the Chapter 11 Plan of Reorganization confirmed on September 21, 2009 resulted in the reversal of an accrued liquidated damages liability of \$180,000.

Forgiveness of debt of approximately \$46,000 represents the discharge of claims and liabilities primarily relates to allowed general, unsecured claims in our Chapter 11 proceedings which represent a 10% reduction in our outstanding accounts payable and liabilities at the time of our Chapter 11 filing.

Loss on investment for the nine months ended September 30, 2009 resulted from the surrender and cancellation of the HepaLife warrant in exchange for an acceleration and prepayment of a \$200,000 receivable payment due from HepaLife.

Interest income of approximately \$0 and \$3,800 was earned for the three months ended September 30, 2009 and 2008, respectively. Interest income of approximately \$200 and \$32,300 was earned for the nine months ended September 30, 2009 and 2008, respectively. The change in interest income primarily reflects lower cash and cash equivalent balances in 2009 from prior year levels and a decline in interest rates earned on our cash account.

Our net loss was approximately \$112,000 and \$308,000 for the three months ended September 30, 2009 and 2008, respectively. Our net loss was approximately \$861,000 and \$2,547,000 for the nine months ended September 30, 2009 and 2008, respectively. The decrease in net loss for the three and nine month periods ended September 30, 2009 compared to the comparable period in 2008 is due to the curtailment of operating and research and development activities due to the lack of capital resources.

Liquidity and Capital Resources

Because we did not have the financial resources to continue to develop our products, on January 9, 2009 we filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Bankruptcy enabled us to continue to seek investors in our equity and bids for the purchase of our assets while working with our creditors. Our Board of Directors determined that, in light of our limited cash position and the current economic conditions and financial markets, the best course of action was to obtain financing and/or sell our assets under bankruptcy protection.

As of September 30, 2009, we had cash of approximately \$194,000, cash held in attorney trust of approximately \$270,000 and current liabilities of approximately \$471,000. Prior to our Bankruptcy filing, we funded our operations primarily from the sale of equity securities and, to a lesser extent, from SBIR grants. Since our Bankruptcy commenced, we have funded our operating expenses and bankruptcy costs through our remaining cash resources and the \$450,000 we received in October 2008 and April 2009 from the sale of certain assets related to HepatAssist™. In addition, we have also received a total of approximately \$800,000 in cash deposits from Acquisition Partners. The foregoing funds constituted our sole source of liquidity. Arbios Acquisition Partners has advised the Company that the remaining \$200,000 called for under the Chapter 11 Plan will be provided in the future on an as-needed basis on terms and conditions to be determined.

As a development stage company, we do not have any bank credit lines or any other sources of capital. All of our operations have been terminated. As part of our Bankruptcy plan of reorganization, we agreed to sell 90% of our common stock to Acquisition Partners in exchange for a total of \$1,000,000 of consideration (\$800,000 in cash for the plan to become effective and \$200,000 after the Effective date to fund operations, as needed). However, any funds

that we will have on hand following the Bankruptcy will not be sufficient to continue the development of our product candidates. Accordingly, the new officers and directors may elect to continue to develop our liver technologies and will have to obtain additional funding to support these efforts.

Our license agreement with Immunocept, LLC has been terminated as part of the bankruptcy proceeding. As part of the termination of this license, we have paid Immunocept \$315,000 as a general unsecured claim and have satisfied this obligation.

We do not believe that inflation has had a material impact on our business or operations.

We do not engage in trading activities involving non-exchange traded contracts. In addition, we have no financial guarantees, debt or lease agreements or other arrangements that could trigger a requirement for an early payment or that could change the value of our assets.

Off- Balance Sheet Arrangements

We are not a party to any off-balance sheet arrangements.

ITEM 3. Qualitative and Quantitative Disclosures about Market Risk.

Not applicable as we are a smaller reporting company.

ITEM 4T. Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures. As of the end of the period covered by this report, our company conducted an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of our disclosure controls and procedures (as defined in Rules 13a-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act). Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our company's disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosures.

(b) Changes in Internal Controls. There was no change in our internal controls, which are included within disclosure controls and procedures, during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls.

(c) Limitations on the Effectiveness of Controls. Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within an organization have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake.

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings.

On January 9, 2009, the Company filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code (the "Bankruptcy Code") with the United States Bankruptcy Court for the District of Delaware (the

“Bankruptcy Court”), Case Number 09-10082 (the “Bankruptcy”). Other than the legal proceedings before the Bankruptcy Court related to our Plan of Reorganization, we are not engaged in any other legal proceedings. On September 21, 2009 the Plan of Reorganization became effective and the Company may emerge from Chapter 11 once the new stock is issued to the shareholders per the terms of the Plan of Reorganization.

ITEM 1A. Risk Factors.

Information regarding risk factors appears under “Factors That May Affect our Business And Our Future Results and Market Price of Our Stock,” included in Item 6 “Management’s Discussion and Analysis of Plan of Operation” of our Annual Report on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission. Except as set forth below, there have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K.

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

ITEM 3. Defaults Upon Senior Securities.

None.

ITEM 4. Submission of Matters to a Vote of Security Holders.

None.

ITEM 5. Other Information.

The Company’s common stock was delisted from the OTC bulletin board in September 2009 due to filing issues related to the emergence from Chapter 11 bankruptcy. The management is in the process of relisting the stock on the OTC bulletin board.

ITEM 6. Exhibits.

- 31.1 Certification of Principal Executive Officer Pursuant to Section 302
- 31.2 Certification of Principal Financial Officer Pursuant to Section 302
- 32 Section 906 certification of periodic financial report by Chief Executive Officer and Chief Financial Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ARBIOS SYSTEMS, INC.

DATE: November 18, 2009

By: /S/ THOMAS J. FAGAN
Thomas J. Fagan
Chief Executive Officer (Principal
Executive Officer)
Chief Financial Officer (Principal
Financial Officer)